Clinical Trial Update: Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update notes ongoing recruitment for evaluating the safety and tolerability of NBI-1065845 as an adjunctive treatment for major depress…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• NBI-1065845

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Major Depressive Disorder | Phase 3 | Status: RECRUITING